{"name":"BioVie Inc.","slug":"biovie","ticker":"BIVI","exchange":"NASDAQ","domain":"biovieinc.com","description":"BioVie Inc. is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and liver diseases. The company's lead product, NEPO-01, is a non-invasive, implantable pump for the treatment of heart failure and other conditions. BioVie Inc. is a relatively small company with a limited market presence.","hq":"Carson City, NV","founded":0,"employees":"","ceo":"Cuong Do","sector":"Biotech — Neurology / Hepatology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$45M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":9266734,"netIncome":-17542120,"cash":21562199,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NE3107","genericName":"NE3107","slug":"ne3107","indication":"Alzheimer's disease","status":"phase_3"}]}],"pipeline":[{"name":"NE3107","genericName":"NE3107","slug":"ne3107","phase":"phase_3","mechanism":"NE3107 is a small-molecule inhibitor of translocator protein (TSPO) that crosses the blood-brain barrier to reduce neuroinflammation and oxidative stress in the central nervous system.","indications":["Alzheimer's disease","Parkinson's disease"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"BioVie Inc. Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"BioVie Inc. reported its financial results for the fourth quarter and full year 2023, with a net loss of $13.1 million and $53.6 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"BioVie Inc. Announces $10 Million Private Placement Financing","summary":"BioVie Inc. announced a private placement financing of $10 million to support its product development and commercialization efforts.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBVNlMtTWgzZVcwbTFHTkdaRW1FampSUmI3c3pXdVlUU0F5RDN2am1DWDJaQ3RGbkZxVnJJSHExNlRVY0Q4QXVHVGk2UG54NXdkb3EzWlNYVE9XWVdxTTJJejFXYkVqakphNEY4Znln?oc=5","date":"2026-04-06","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Biovie Inc (BIVI) - Stock Titan","headline":"If You Invested $1,000 in Biovie Inc (BIVI)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNaFlVUWNqcTlZMlM3UzJrWm9rR25xdUhfVGVaMnd5YWM2YlJWVkZQNzNEX0ZER3l5ZEhxTFlIMEdseWlkSkpfNHBhQUhzR1BWRnJ5eEVhMTZoQVJZQUc4Ml8tWVUzNl9lS0NMSXQ3bndUWkRWZFFKZGd4R0Y3aVNCYjZrWWtVR0FuVWFzY3VJa3dFME1WbVVGXzRBcW5DYm9FOXM0OVhQTkcyRFYtN1hzbDJQNVE4Qjg?oc=5","date":"2026-03-12","type":"trial","source":"Stock Titan","summary":"Parkinson’s trial drug heads to 2026 Alzheimer’s & Parkinson’s meeting - Stock Titan","headline":"Parkinson’s trial drug heads to 2026 Alzheimer’s & Parkinson’s meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQSXB0VXl2UnR3RXVsTDVXc3BXR1NHUmFWcV9wNjhBdXJLS1BRQWhzRVhsOGZiNEdYNGZtZk5CSnU1cWFoZERtSWItZGlnMjctM0FZYTcyWFVIY2x5eHBNeUJvRjRWQlY4bTVpMG5tYTdUZXJGa251X0wzckx1OUl2X3FoelBSdkY0SkROYW1JaVlTZkxLdTZfM1hmNzlHQkZaVWxaRnZ5NFJLUlBJWDhGU2hXSjRIaHhiQTAxTjNvZnB6Z2E2ZkZFMEtZcTdGOWJjQ1E?oc=5","date":"2026-03-12","type":"trial","source":"proactiveinvestors.com","summary":"BioVie to present Parkinson’s study data at AD/PD 2026 conference - proactiveinvestors.com","headline":"BioVie to present Parkinson’s study data at AD/PD 2026 conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQaHl0QU5oN19aWUZKTENPaGhUaXVUTlZSZ2ZZb19qLXFITy1CZW94dXpmU2FrU2EzbHU0NEVHZEs5TXFlWnItQnNtdUoyeVRmZU52LXpuVkFLb0t1ZnZCdzVQS3dNQU92eWstc2tETXNsS0wwVzJaVjRBYU4xQi12ZTdQV2Zpa0g5LVg1d3NoNlNUazA1WUZJ?oc=5","date":"2026-03-02","type":"pipeline","source":"The Wall Street Transcript","summary":"Interview with the President and CEO: BioVie Inc. (NASDAQ:BIVI) - The Wall Street Transcript","headline":"Interview with the President and CEO: BioVie Inc. (NASDAQ:BIVI)","sentiment":"neutral"},{"date":"2026-02-06","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q FOR PERIOD ENDING DECEMBER 31, 2025","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2025-11-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2025-11-10","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q FOR PERIOD ENDING SEPTEMBER 30, 2025","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNQ0EtZnFLSEhHODZ2SjBJSUxoaVNhUUM5NzhNVzhhdFhnSU9jUW1jZ1FMSkhpd2hXa09XMzhUTWxvQVpDT0VVZUQ3ZmVNTFZick1ZcnV3dE5wN3gwWkhWWVNockxzeU5qVDU5OXNnZWZYRm95M2hXNnVDZGxYY2t3TUVKOA?oc=5","date":"2025-08-11","type":"pipeline","source":"Yahoo Finance","summary":"BioVie Inc. Announces Closing of $12 Million Public Offering - Yahoo Finance","headline":"BioVie Inc. Announces Closing of $12 Million Public Offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNZnlwSDVGM2t6Q293d01DeWxjdVIyTU1OSHFVeE5LNS15RGotSTFZZUliTVBKUkVvcEQtTDNsMkFpcjhhVlRNX2ZWSVEwUnVwcjZFQUJWZjdUd3NNMmxEMlZHUURzTkpqUlRFUGxCX0xabTJ4MVp4cVRtazZDQ1loTFpHWEU5S1U?oc=5","date":"2024-08-06","type":"pipeline","source":"Yahoo Finance","summary":"BioVie Inc. Announces Reverse Stock Split - Yahoo Finance","headline":"BioVie Inc. Announces Reverse Stock Split","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNaVpWR3hLR0JCUzM2VGdlaFRDdVJlcHNqZnd6Q3Z1THJFRzliREpHNnNPV041ZEFVdVgwR0J5QkFUUEF0akRKdF9ZT1QtUF9fMXNvZVVOQjcwdHJpZWFTTkRPU3E5U3Jqb2RrOXZTTmpyZ2c2Q0p6dGZJQ2dxUHhWR2NtakM3VG5pajlXemVSeE8wcUhjdjJTcDhPbERwUkd6SGswdnJCOWZqNVRTN3F1aGk3X0t3Zw?oc=5","date":"2024-03-04","type":"pipeline","source":"proactiveinvestors.ca","summary":"BioVie prices proposed equity raise - proactiveinvestors.ca","headline":"BioVie prices proposed equity raise","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOVUdKZEh1NE52ejNKZmg0cTRLa0pNV2o4OGc2bkxTQWlyWlpWbEl2b3hiUGFBR2t1QUJTM245aFlNSEsxQUNCc21GYXFERV93VldVSmQxajM2M25NTmJuU3NJT0pSeWtYWDN3ZTUzQmhhci1qQ0ozalVKNmRHY1Nhd2RlS0tBald2YkdFTTNadG1IOHprQ3BBbTRiN2tON2xsYndrYWh5c294clFoQ2xhbXNNS2t6cUFMWk1CbnkxYkZWOUNCbXBJc3lUdmZzckI2N1YtZ0JKMA?oc=5","date":"2023-11-13","type":"trial","source":"proactiveinvestors.com","summary":"BioVie presents positive safety data from Phase 2 liver disease trial - proactiveinvestors.com","headline":"BioVie presents positive safety data from Phase 2 liver disease trial","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxNTDlhamY1emp0RkVKdlo4eDBfMlo3eFNtS2laX1kyTm1NRmJLcXhZdG9MV01jbEVYSURPNFRPTHRJUEVnS2FlekN4MTBhZVZYODRZbHBjMFYzcmJoTmJVeURtcXZsRXdIaDRYYk1rWVZvMHA1UElwT1JsVl9URWVWV0lpMjlGSG5ZVkhsRW4tbE5zTzVKQkd1VEplblZ2bS03dm9SR0VnNHBJU3dtNTVKZ0dMdU00SG1DUVZ0WWwxVjE0QmRhcW9qWUpzM01OOXg5TzNvenpYQTVPcUYzUGhSb1RGZTVKUlVNamtCSk9pZGxXN05CUEtpU2p3?oc=5","date":"2023-05-16","type":"trial","source":"proactiveinvestors.com","summary":"BioVie presents rationale for NE3107 trial in Parkinson's Disease treatment at IAPRD in Chicago - proactiveinvestors.com","headline":"BioVie presents rationale for NE3107 trial in Parkinson's Disease treatment at IAPRD in Chicago","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE1iRnhLNFhScldncHBpQldUWDRHOVg5TE51TllfZk1lYl80M1dWNmEzbEg5cktISkZKOENpejRFNEJ5Q1AxdlJVbVdHOFB4bXhOZHBJTWtSVHFoc1E4RU9vV3AwSE5Ybzhv?oc=5","date":"2022-10-27","type":"pipeline","source":"proactiveinvestors.com","summary":"BioVie Inc Share Price - BIVI, RNS News, Articles, Quotes, & Charts (NASDAQ:BIVI) - proactiveinvestors.com","headline":"BioVie Inc Share Price - BIVI, RNS News, Articles, Quotes, & Charts (NASDAQ:BIVI)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE5OVkdIeEV2RU96aFRoVThPbExDVV93Q0hqSzlac1lFZ0RlcHd1amYtU3pXZWlUTU9PSzh0bW1LdWUwUzlmODhfeC0xTUQ1UTlrWFE?oc=5","date":"2018-02-21","type":"pipeline","source":"Yahoo! Finance Canada","summary":"BioVie Inc. (BIVI) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"BioVie Inc. (BIVI) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Bristol Myers Squibb","Merck & Co."],"therapeuticFocus":["Neurology","Hepatology"],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":9266734,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-17542120,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":21562199,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}